Scarica l'app Stockscreener
29.30
1.12%
-0.215
Precedente Chiudi:
$29.52
Aprire:
$29.22
Volume 24 ore:
42,801
Relative Volume:
0.10
Capitalizzazione di mercato:
$1.29B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.24%
1M Prestazione:
+23.32%
6M Prestazione:
+196.04%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$28.98
$30.26
Intervallo di 1 settimana:
$27.54
$31.93
Portata 52W:
$6.71
$31.93
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Confronta MAZE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
29.36 | 1.43B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.38 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.40 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.92 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
828.09 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
314.25 | 34.99B | 4.56B | -176.77M | 225.30M | -1.7177 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze Therapeutics Inc. recovery potential after sell offPortfolio Risk Summary & Fast Entry Momentum Alerts - newser.com
Pattern recognition hints at Maze Therapeutics Inc. upsideWeekly Trade Review & Long-Term Safe Investment Plans - newser.com
Does Maze Therapeutics Inc. qualify in momentum factor screeningNew Guidance & Verified Momentum Stock Watchlist - newser.com
Developing predictive dashboards with Maze Therapeutics Inc. dataJuly 2025 Opening Moves & Advanced Technical Signal Analysis - newser.com
Will Maze Therapeutics Inc. outperform the marketPortfolio Update Report & Verified Momentum Watchlists - newser.com
What is the fair value of Maze Therapeutics Inc. stock nowJuly 2025 Levels & Precise Buy Zone Identification - newser.com
Can Maze Therapeutics Inc. stock beat market expectations this quarterPortfolio Profit Report & Real-Time Buy Zone Alerts - newser.com
Why Maze Therapeutics Inc. is moving todayWeekly Profit Recap & Verified High Yield Trade Plans - newser.com
Can Maze Therapeutics Inc. stock deliver sustainable ROEJuly 2025 Action & Real-Time Stock Price Movement Reports - nchmf.gov.vn
Is Maze Therapeutics Inc. stock a top momentum playTrade Exit Summary & Community Consensus Stock Picks - nchmf.gov.vn
Will Maze Therapeutics Inc. stock rally after Fed decisionsQuarterly Market Review & Technical Entry and Exit Alerts - nchmf.gov.vn
What drives Maze Therapeutics Inc stock priceDividend Growth Stocks & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Portfolio Update: Will Maze Therapeutics Inc. stock benefit from AI adoptionMarket Volume Report & Verified Momentum Watchlists - nchmf.gov.vn
Will Maze Therapeutics Inc. stock benefit from AI adoptionPortfolio Return Summary & Verified Chart Pattern Signals - nchmf.gov.vn
ETFs Investing in Maze Therapeutics, Inc. Stocks - TradingView
Weiss Ratings Reaffirms "Sell (D)" Rating for Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Can a trend reversal in Maze Therapeutics Inc. lead to recovery2025 Fundamental Recap & Capital Protection Trade Alerts - newser.com
How to use a screener to detect Maze Therapeutics Inc. breakoutsWall Street Watch & Free Daily Entry Point Trade Alerts - newser.com
Pompe Disease Market Research 2025: Treatment, Route of Administration, and Region Analysis and Forecast to 2035 Featuring Amicus Therapeutics, Astellas, BioMarin, Maze Therapeutics, Oxyrane ParasailResearchAndMarkets.com - The AI Journal
Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year HighWhat's Next? - MarketBeat
Maze Therapeutics Appoints Herve Hoppenot as Board Chairman - MarketScreener
What technical models suggest about Maze Therapeutics Inc.’s comeback2025 Major Catalysts & Long Hold Capital Preservation Plans - newser.com
Maze Therapeutics appoints Hervé Hoppenot as chairman of the board - Investing.com
Maze Therapeutics Appoints Hervé Hoppenot as Chairman - TipRanks
Maze Therapeutics appoints Hervé Hoppenot as board chairman - Investing.com India
Maze Therapeutics appoints Hervé Hoppenot as board chairman By Investing.com - Investing.com Australia
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewswire
Detecting price anomalies in Maze Therapeutics Inc. with AI2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
Predicting Maze Therapeutics Inc. trend using moving averages2025 Top Decliners & Verified Swing Trading Watchlist - newser.com
Maze Therapeutics (MAZE): Assessing Current Valuation Following a 78% Monthly Share Price Surge - Sahm
Maze Therapeutics (MAZE): Assessing Valuation After 78% 30-Day Share Price Surge - Yahoo Finance
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Non sono disponibili dati finanziari per Maze Therapeutics Inc (MAZE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):